Austin, TX – [Date, e.g., October 26, 2023] – Hanger Inc., a leading provider of orthotic and prosthetic (O&P) patient care services and solutions, has announced a landmark acquisition that promises to reshape the landscape of prosthetic technology. The company has acquired Liberating Technologies Inc. (LTI), a distinguished research organization renowned for its pioneering work in advanced O&P solutions. This strategic move is poised to significantly bolster Hanger’s research and innovation capabilities, accelerating the development and deployment of next-generation prosthetic technologies for patients worldwide.
The acquisition of LTI, previously owned by Coapt, marks a pivotal moment for Hanger Inc., underscoring its unwavering commitment to advancing clinical practice and improving patient outcomes through evidence-based care. By integrating LTI’s specialized research team and its robust portfolio of government-funded initiatives, Hanger aims to fast-track breakthroughs in areas such as intuitive prosthesis control, enhanced comfort solutions, and optimized functional outcomes for individuals utilizing prosthetic devices. This expansion of Hanger’s internal R&D prowess is expected to foster a new era of innovation, bridging the gap between cutting-edge research and direct patient application.
Strategic Move to Accelerate Next-Generation Solutions
Hanger Inc. has long stood at the forefront of the orthotics and prosthetics industry, serving millions of patients with a comprehensive range of custom O&P devices, clinical care, and support services. The company’s vision extends beyond mere provision; it encompasses a deep-seated commitment to innovation that continually pushes the boundaries of what’s possible in rehabilitative care. The acquisition of Liberating Technologies Inc. is a testament to this commitment, representing a calculated and impactful strategic decision designed to solidify Hanger’s position as a global leader in O&P innovation.
LTI brings to Hanger a unique blend of scientific expertise and a proven track record in securing high-impact, government-funded grants. Since its inception in 2000 and particularly since 2008, LTI’s dedicated research team has been instrumental in exploring and developing advanced concepts that address critical challenges faced by prosthesis users. Their work is characterized by a rigorous scientific approach aimed at translating complex research into practical, life-changing technologies. This synergy of Hanger’s extensive clinical network and LTI’s focused research capabilities creates a powerful engine for innovation, promising to deliver solutions that are not only technologically advanced but also clinically relevant and patient-centric.
The integration of LTI is expected to streamline the innovation pipeline, from initial concept generation and research to clinical testing and eventual widespread adoption. This vertical integration of research and care delivery is crucial in an industry where rapid technological advancements can dramatically improve the quality of life for individuals with limb loss. Hanger’s existing infrastructure, including its vast network of clinics and patient data, will provide LTI researchers with unparalleled access to real-world insights, enabling them to refine and validate their technologies with greater efficiency and precision. The overarching goal is clear: to accelerate the development of prosthetics that offer greater functionality, comfort, and a more seamless integration into the daily lives of users.
Unpacking the Strategic Rationale
The orthotics and prosthetics market is a dynamic sector, driven by an aging global population, increasing prevalence of diabetes and vascular diseases leading to amputations, and continuous technological advancements. Within this evolving landscape, companies like Hanger Inc. are under constant pressure to innovate and provide superior solutions. The acquisition of Liberating Technologies Inc. is not merely an expansion; it is a strategic reinforcement of Hanger’s core mission and a proactive step to secure its leadership in an increasingly competitive and technologically demanding field.
Synergistic Strengths: Hanger’s Reach Meets LTI’s Innovation
Hanger Inc. operates one of the largest networks of O&P patient care clinics in the United States, providing a critical service to thousands of individuals daily. Its strength lies not only in its geographical reach but also in its comprehensive approach to patient care, encompassing everything from initial assessment and custom device fabrication to rehabilitation and ongoing support. This extensive clinical footprint offers a unique advantage: a direct conduit to patient needs, challenges, and feedback, which is invaluable for guiding research and development efforts.
Liberating Technologies Inc., on the other hand, represents the vanguard of O&P research. Its specialized focus on cutting-edge, high-impact concepts, often funded through competitive government grants, signifies its capacity to push scientific boundaries. LTI’s expertise lies in fundamental and applied research, exploring novel approaches to prosthesis control, user interface, and overall functionality. The confluence of Hanger’s broad clinical exposure and LTI’s deep research capabilities creates a powerful synergy. Hanger gains immediate access to a dedicated team of researchers and a pipeline of innovative projects, while LTI benefits from Hanger’s vast clinical data, technical resources, and direct access to patient populations for testing and validation.
This strategic alignment addresses a critical need within the O&P industry: bridging the gap between academic research and practical clinical application. Often, groundbreaking research remains confined to laboratories due to a lack of resources for clinical trials, manufacturing, or distribution. By bringing LTI into the Hanger ecosystem, Hanger is creating a seamless pathway for innovative ideas to transition from concept to product, ultimately benefiting patients sooner. The acquisition reinforces Hanger’s "continued commitment to expanding research and development, advancing clinical practice, and improving patient outcomes through evidence-based care," as articulated by its CEO. It’s a move that recognizes the long-term value of investing in foundational research to drive sustainable, impactful innovation across the entire O&P spectrum.
A Legacy of Innovation: The Journey of Liberating Technologies Inc.
The story of Liberating Technologies Inc. is one of persistent inquiry and dedication to scientific advancement. From its humble beginnings, LTI has carved out a niche as a respected and influential player in the specialized world of orthotic and prosthetic research. Its journey highlights the critical role that focused, independent research organizations play in pushing the boundaries of medical technology.
From Foundation to Frontier Research
Founded in the year 2000, Liberating Technologies Inc. was established with a clear mission: to conduct innovative research that would lead to significant improvements in O&P technologies. For several years, LTI steadily built its capabilities and reputation, but it was from 2008 onwards that its impact truly began to accelerate. This period marked a significant turning point as LTI’s specialized research team successfully secured numerous government-funded grants. These grants are highly competitive and serve as a strong validation of LTI’s scientific rigor, the potential impact of its proposed research, and the expertise of its personnel.
The nature of LTI’s grant-funded initiatives speaks volumes about its forward-thinking approach. Their projects have consistently focused on "cutting-edge, high-impact concepts" aimed at developing "next-generation technologies" for the O&P field. This includes work on complex challenges such as improving the intuitive control of prosthetic limbs, enhancing user comfort, and addressing critical health concerns associated with prosthesis use.
For instance, LTI’s research has delved into:
- Advancing voice-recognition technology for improved prosthesis control: This aims to provide users with a more natural and less physically demanding method of controlling their prosthetic devices, potentially allowing for finer motor control and increased autonomy. Imagine a user being able to simply speak a command to adjust grip strength or limb position, significantly enhancing their interaction with the device.
- Developing socket cooling systems to support residual limb skin health: A common and debilitating issue for prosthesis users is skin breakdown and discomfort due to heat and moisture buildup within the prosthetic socket. LTI’s work in this area seeks to create active cooling solutions that can maintain optimal skin temperature and reduce friction, thereby preventing complications, improving comfort, and increasing the duration a prosthesis can be worn daily.
- Optimizing electrode configurations for pattern recognition control: Pattern recognition is a sophisticated method that interprets electrical signals from residual limb muscles to provide intuitive control over prosthetic hands and arms. LTI’s research in optimizing electrode placement and configuration is crucial for enhancing the accuracy and reliability of these systems, helping prosthesis users achieve more fluid, natural, and optimal functional outcomes in their daily activities.
Prior to this acquisition by Hanger, LTI was under the ownership of Coapt, a company itself known for its innovative neural interface technologies. This previous association further underscores LTI’s position within a lineage of advanced prosthetic development, focusing on the interface between the human body and artificial limbs. The expertise cultivated during its independent operation and under Coapt’s stewardship now forms a vital asset for Hanger, integrating a powerhouse of research directly into its operational framework. LTI’s legacy is one of persistent problem-solving, driven by a profound understanding of both the biomechanical and human aspects of prosthetic technology.
Official Voices on a Landmark Acquisition
The strategic importance of Hanger Inc.’s acquisition of Liberating Technologies Inc. is clearly articulated by the leadership of both organizations. Their statements reveal a shared vision for the future of orthotics and prosthetics, emphasizing patient-centric innovation and collaborative advancement. These official responses highlight the immediate benefits of the partnership and cast a long-term outlook on its potential to revolutionize patient care.
Leadership Perspectives on Growth and Patient Impact
Pete Stoy, Hanger’s Chief Executive Officer, underscored the profound implications of bringing LTI into the Hanger fold. "The addition of LTI strengthens Hanger’s continued commitment to expanding research and development, advancing clinical practice, and improving patient outcomes through evidence-based care," Stoy remarked. His statement reflects a holistic strategy where R&D is not an isolated function but an integral component of Hanger’s mission to deliver superior patient care. The emphasis on "evidence-based care" is particularly significant, indicating a commitment to rigorous scientific validation that ensures new technologies are not only innovative but also clinically effective and safe.
Stoy further elaborated on the broader aspirations of the acquisition, stating, "This partnership also reflects our ambition to accelerate global technological progress for O&P patients and to join forces with current and future collaborators to drive the next generation of innovation." This vision extends beyond Hanger’s immediate operational boundaries, hinting at a desire to influence the global O&P community. By accelerating technological progress, Hanger aims to set new industry standards and foster an environment of open collaboration, inviting other innovators and researchers to contribute to a collective advancement that ultimately benefits all O&P patients worldwide. This ambition positions Hanger as a thought leader and a catalyst for industry-wide evolution.
Complementing Stoy’s macroscopic view, Todd Farrell, PhD, who now serves as Vice President of Research and Development for Hanger (and previously played a key role at LTI), expressed enthusiasm for the tangible benefits LTI will gain. "We are excited about this opportunity to become a part of the Hanger ecosystem, which will provide LTI with the technical resources, and the access to clinical insights and clinical data that can help us further drive and enhance innovation," Dr. Farrell commented. His perspective from within the research team sheds light on the practical advantages of the acquisition. For a research organization, access to robust technical resources—ranging from advanced laboratory equipment to specialized personnel—is critical. Even more crucial is the access to clinical insights and real-world patient data. Hanger’s extensive network of clinics generates a wealth of de-identified data that can inform research, validate hypotheses, and guide the iterative development process, ensuring that LTI’s innovations are precisely tailored to actual patient needs and experiences. This feedback loop is often the missing link between theoretical research and impactful clinical application.
The combined sentiments from Stoy and Farrell paint a clear picture: this acquisition is a carefully considered strategic move that promises mutual benefits. Hanger gains a dedicated research powerhouse, enhancing its innovation capabilities and reinforcing its commitment to leadership. LTI, in turn, gains unparalleled access to the resources, data, and clinical network necessary to elevate its groundbreaking research to a new level of impact and accessibility. This partnership is poised to be a powerful driver of progress, fostering an environment where scientific discovery and practical patient care converge to create a healthier, more functional future for individuals with limb loss.
Integration and Future Trajectory
The success of any acquisition hinges not just on the strategic alignment of the entities but crucially on the effective integration of operations, personnel, and vision. For Hanger Inc. and Liberating Technologies Inc., the integration plan is designed to maximize synergy, ensuring that LTI’s research capabilities are amplified within Hanger’s broader innovation ecosystem. This structured integration aims to accelerate the translation of research findings into tangible patient benefits.
Catalyzing Innovation within the Hanger Ecosystem
Liberating Technologies Inc. will be strategically integrated into two key innovation pillars within Hanger: Hanger Ventures and the Hanger Institute for Clinical Research and Education. This dual integration is deliberate and designed to leverage LTI’s strengths across different phases of innovation and development.
Hanger Ventures is the company’s dedicated arm for investing in and incubating disruptive technologies and innovative solutions that can transform the O&P industry. By joining Hanger Ventures, LTI gains access to strategic oversight, potential further investment, and a direct pathway for commercialization of its research outcomes. Hanger Ventures acts as a bridge between cutting-edge ideas and market readiness, providing the necessary support to scale promising technologies from the lab to widespread clinical use. This alignment ensures that LTI’s projects are not only scientifically sound but also have a clear path to market adoption and patient impact.
Simultaneously, LTI will become a vital component of the Hanger Institute for Clinical Research and Education. The Hanger Institute is renowned for its commitment to advancing clinical practice through rigorous research, evidence-based methodologies, and comprehensive professional education. This integration provides LTI researchers with an unparalleled platform for conducting clinical trials, validating their technologies in real-world settings, and collaborating with Hanger’s vast network of O&P clinicians. Access to the Institute’s resources will facilitate faster iteration cycles for LTI’s projects, allowing for immediate feedback from practitioners and patients, which is crucial for refining and optimizing new prosthetic solutions. Furthermore, the Institute’s educational arm will be instrumental in disseminating LTI’s research findings and training clinicians on the effective use of new technologies, ensuring rapid and knowledgeable adoption across Hanger’s extensive network.
The LTI team will continue to lead its current grant-funded initiatives, which include critical areas like advancing voice-recognition technology for prosthesis control, developing innovative socket cooling systems for residual limb health, and optimizing electrode configurations for pattern recognition control. The continuity of these projects under Hanger’s stewardship ensures that ongoing research momentum is maintained and enhanced. Moreover, the integration provides LTI with the bandwidth and resources to actively pursue new research and development opportunities, allowing them to expand the scope and impact of their work. This could involve exploring novel materials, advanced robotics, artificial intelligence in prosthetic design, or personalized medicine approaches.
Crucially, this acquisition also completes the integration of the Coapt portfolio into the Hanger family. Hanger had previously announced the acquisition of Coapt, LTI’s former owner. Coapt is known for its advanced neural interface technologies, which allow for more intuitive control of prosthetic devices by interpreting muscle signals. With LTI now part of Hanger, the full spectrum of Coapt’s pioneering work, from foundational research (LTI) to advanced commercial products (Coapt), is consolidated under one roof. This creates a powerful, vertically integrated innovation chain, allowing Hanger to control the entire lifecycle of advanced prosthetic technology development, from initial scientific discovery to patient delivery. This unified approach fosters seamless transitions between research, development, and clinical application, accelerating the pace at which transformative technologies reach the patients who need them most.
Broader Implications for the O&P Field
The acquisition of Liberating Technologies Inc. by Hanger Inc. is more than just a corporate transaction; it carries significant implications for the entire orthotics and prosthetics field. This strategic move is poised to set new benchmarks in patient care and technology, influencing research directions, market dynamics, and ultimately, the quality of life for millions of individuals globally.
Setting New Benchmarks in Patient Care and Technology
One of the most immediate implications is the potential for accelerated innovation. By integrating a dedicated research powerhouse like LTI with Hanger’s extensive clinical infrastructure, the time from discovery to patient application can be drastically reduced. This means that breakthroughs in areas like intuitive control systems, advanced materials, and personalized prosthetic solutions could reach the market much faster, directly translating into improved functionality and comfort for users. Hanger’s commitment to "accelerate global technological progress" suggests a leadership role in driving the industry forward, potentially inspiring other O&P providers to increase their investment in R&D.
The acquisition also strengthens the trend towards evidence-based care within the O&P industry. LTI’s grant-funded research is inherently rigorous and scientifically validated. When combined with Hanger’s capacity for large-scale clinical trials and data collection, the resulting innovations will be backed by robust evidence, enhancing clinician confidence and improving patient outcomes. This focus on scientific validation helps elevate the entire field, pushing for higher standards of product development and clinical practice.
From a market perspective, this consolidation of research and clinical services within Hanger could lead to a more competitive landscape. As Hanger pioneers new technologies, it may challenge other industry players to innovate more rapidly to keep pace. This competition, in turn, can spur further advancements across the board, ultimately benefiting consumers through a wider array of more effective and accessible prosthetic options. The market for prosthetics and orthotics is projected to grow substantially in the coming years, driven by factors such as an aging population, increasing incidence of chronic diseases leading to amputations (like diabetes), and advancements in medical technology. Hanger’s acquisition of LTI positions it exceptionally well to capitalize on this growth and shape the future direction of the market.
Furthermore, the emphasis on specific research areas such as voice-recognition technology, socket cooling systems, and optimized electrode configurations addresses some of the most persistent challenges faced by prosthesis users: discomfort, lack of intuitive control, and skin health issues. Solving these problems can profoundly impact a user’s daily life, enabling greater independence, participation in social and professional activities, and overall well-being. The development of more comfortable and user-friendly devices can significantly reduce rejection rates of prostheses, ensuring that more individuals benefit from these life-changing technologies.
Beyond direct patient benefits, the acquisition could also have an economic impact. Increased investment in R&D can create high-skilled jobs in research, engineering, and clinical roles. It also signifies a commitment to domestic innovation, potentially bolstering the medical technology sector within the regions where Hanger and LTI operate. The intellectual property generated through LTI’s enhanced research efforts will further solidify Hanger’s proprietary technology portfolio, reinforcing its market leadership and long-term viability. The integration of data-driven insights from Hanger’s vast patient base into LTI’s research methodology will foster a virtuous cycle of innovation, ensuring that future developments are continually informed by real-world needs and experiences.
Conclusion: A Unified Vision for a Healthier Future
Hanger Inc.’s acquisition of Liberating Technologies Inc. represents a bold and visionary step forward in the orthotics and prosthetics industry. It is a powerful testament to Hanger’s enduring commitment to innovation, patient care, and leadership in a field that profoundly impacts human lives. By uniting Hanger’s extensive clinical expertise and broad patient reach with LTI’s specialized research prowess and proven track record of securing high-impact government grants, the combined entity is poised to accelerate the development of transformative prosthetic technologies.
This strategic alignment promises to bridge the critical gap between groundbreaking research and practical clinical application, ensuring that next-generation solutions—from intuitive control systems to enhanced comfort features—reach patients more rapidly and effectively. The integration of LTI into Hanger Ventures and the Hanger Institute for Clinical Research and Education will foster a dynamic ecosystem where innovation is nurtured, validated, and scaled. With the full Coapt portfolio now consolidated, Hanger has created a comprehensive innovation pipeline, poised to drive significant advancements across the entire spectrum of prosthetic development.
The implications for the O&P field are far-reaching. This acquisition is set to elevate industry standards, foster greater competition in innovation, and ultimately enhance the quality of life for individuals with limb loss worldwide. As Hanger Inc. continues to expand its research and development capabilities, it reinforces its position as a global leader, dedicated to advancing clinical practice and improving patient outcomes through evidence-based, cutting-edge solutions. The future of orthotics and prosthetics looks brighter and more innovative than ever, driven by a unified vision for a healthier, more mobile, and more liberated future.
